Targeting ERβ/TGFβ1/SMAD3 signals with FDA-approved anti-estrogen Faslodex or with an ERβ selective antagonist significantly reduced RCC tumor growth and invasion [78]. The gene discussed is TGFB1; the disease is renal cell adenocarcinoma.